Prophylaxis and treatment of pneumococcal bacteremia by immune globulin intravenous in a mouse model

Clinical Immunology and Immunopathology
D S Chudwin

Abstract

A mouse model was developed to test the efficacy of human immune globulin intravenous (IGIV) in prevention and treatment of pneumococcal bacteremia. Mice pretreated with IGIV and then challenged with types 3 or 7F Streptococcus pneumoniae had significantly increased (P less than 0.025) survival compared to controls. Three commercially available IGIV preparations were all effective in significantly increasing (P less than 0.025) survival in mice already infected. Mice treated with IGIV plus penicillin had significantly greater (P less than 0.05) survival than those who received penicillin alone. IGIV may be useful in treatment of pneumococcal bacteremia.

Citations

Oct 1, 1991·Journal of Pediatric Oncology Nursing : Official Journal of the Association of Pediatric Oncology Nurses·K MeeskeK Reed
Jan 28, 2014·Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society·Antonia ChenYiRong Zeng
Apr 24, 2009·Clinical and Vaccine Immunology : CVI·Nikkol MelnickEdwin W Ades
Jan 21, 2000·FEMS Microbiology Reviews·P H Mäkelä

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Related Papers

Journal of Medical Primatology
D S ChudwinG Schiffman
The Journal of Laboratory and Clinical Medicine
S V Hetherington, G S Giebink
© 2022 Meta ULC. All rights reserved